|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,804.00 DKK | +0.78% |
|
+0.78% | -11.00% |
| 04-15 | Nordic Equities in North America - Astra Zeneca Gains 0.9 Percent | FW |
| 04-14 | Genmab A/S Provides Net Sales of Darzalex Results for the First Quarter of 2026 | CI |
Company Valuation: Genmab A/S
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 172,063 | 192,229 | 140,770 | 94,810 | 124,862 | 110,749 | - | - |
| Change | - | 11.72% | -26.77% | -32.65% | 31.7% | -11.3% | - | - |
| Enterprise Value (EV) 1 | 152,725 | 169,905 | 112,635 | 73,709 | 114,029 | 111,907 | 110,327 | 100,619 |
| Change | - | 11.25% | -33.71% | -34.56% | 54.7% | -1.86% | -1.41% | -8.8% |
| P/E ratio | 57.8x | 35.2x | 32.6x | 12.3x | 20.9x | 23.6x | 15.9x | 10.2x |
| PBR | 7.82x | 7.07x | 4.5x | 2.68x | 3.47x | 2.55x | 2.21x | 1.81x |
| PEG | - | 0.4x | -1.5x | 0.1x | -1x | -1.1x | 0.3x | 0.2x |
| Capitalization / Revenue | 20.3x | 13.2x | 8.54x | 4.4x | 5.31x | 4.03x | 3.41x | 2.76x |
| EV / Revenue | 18x | 11.6x | 6.84x | 3.42x | 4.85x | 4.08x | 3.39x | 2.51x |
| EV / EBITDA | 46.8x | 25.3x | 20.1x | 10.4x | 15.9x | 12.5x | 9.08x | 6x |
| EV / EBIT | 50.6x | 26.7x | 21.2x | 10.5x | 17x | 15.1x | 10.8x | 6.8x |
| EV / FCF | 77.3x | 47.3x | 16.1x | 9.72x | 15.7x | 21.3x | 9.26x | 5.28x |
| FCF Yield | 1.29% | 2.12% | 6.23% | 10.3% | 6.36% | 4.7% | 10.8% | 18.9% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 45.54 | 83.65 | 66.02 | 121.4 | 97.08 | 76.54 | 113.2 | 177.4 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 8,482 | 14,595 | 16,474 | 21,526 | 23,497 | 27,448 | 32,519 | 40,069 |
| EBITDA 1 | 3,266 | 6,719 | 5,616 | 7,116 | 7,175 | 8,980 | 12,157 | 16,778 |
| EBIT 1 | 3,018 | 6,357 | 5,321 | 7,003 | 6,727 | 7,405 | 10,169 | 14,786 |
| Net income 1 | 3,008 | 5,522 | 4,352 | 7,844 | 6,083 | 4,814 | 7,235 | 11,310 |
| Net Debt 1 | -19,338 | -22,324 | -28,135 | -21,101 | -10,833 | 1,157 | -422.4 | -10,130 |
| Reference price 2 | 2,630.00 | 2,941.00 | 2,155.00 | 1,492.50 | 2,027.00 | 1,804.00 | 1,804.00 | 1,804.00 |
| Nbr of stocks (in thousands) | 65,423 | 65,362 | 65,322 | 63,524 | 61,599 | 61,391 | - | - |
| Announcement Date | 2/16/22 | 2/22/23 | 2/14/24 | 2/12/25 | 2/17/26 | - | - | - |
1DKK in Million2DKK
Estimates
P/E ratio, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 23.49x | 4.08x | 12.45x | -.--% | 17.49B | |
| 29.59x | 7.86x | 23.36x | 0.05% | 52.7B | |
| 17.05x | 5.12x | 11.64x | 1.73% | 44.07B | |
| -56.08x | 17.84x | -60.31x | -.--% | 31.19B | |
| -19.28x | 4.64x | -9.17x | -.--% | 26.03B | |
| 28.36x | 5.54x | 15.41x | -.--% | 18.88B | |
| -20.14x | 2414.99x | -28.03x | -.--% | 19.5B | |
| -429.08x | 35.92x | 1977.32x | -.--% | 17.76B | |
| -618.01x | 37.38x | -1063.35x | -.--% | 15.49B | |
| -111.75x | 7.83x | -220.91x | -.--% | 12.2B | |
| Average | -115.59x | 254.12x | 65.84x | 0.18% | 25.53B | |
| Weighted average by Cap. | -70.28x | 195.45x | 60.90x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- GMAB Stock
- Valuation Genmab A/S
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition